Header Logo

Vincent H Tam

TitleProfessor
InstitutionUniversity of Houston
DepartmentPharmaceutical Health Outcomes and Policy
Address4800 Calhoun Rd
Houston TX 77004
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01AI140287     (TAM, VINCENT H)Aug 15, 2018 - Jun 30, 2029
    NIH
    Personalized Antimicrobial Combinations to Combat Resistance
    Role: Principal Investigator
    R56AI111793     (TAM, VINCENT H)Aug 1, 2014 - Jul 31, 2016
    NIH
    Optimized Antimicrobial Combinations to Suppress Resistance
    Role: Principal Investigator
    R15AI089671     (TAM, VINCENT H)Mar 29, 2010 - Sep 28, 2013
    NIH
    Clinical Pharmacology of Polymyxin B
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Teran NS, Hudson CS, Phe K, Wang Y, Zhang Y, Chen H, Nigo M, Tam VH. Reduction of vancomycin-associated acute kidney injury with montelukast. J Infect Dis. 2025 Jan 15. PMID: 39812174.
      Citations:    Fields:    
    2. Finch NA, Granillo A, Pouya N, Bhimraj A, Miller WR, Tam VH. Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 Jan; 45(1):66-69. PMID: 39629915; PMCID: PMC11757030.
      Citations:    Fields:    
    3. Carvajal LP, Rincon S, Gomez Villegas SI, Matiz-Gonzalez JM, Ordo?ez K, Santamaria A, Ospina Navarro L, Beltran J, Guevara F, Mendez YR, Salcedo S, Porras A, Valencia-Moreno A, Greenia H, Deyanov A, Baptista R, Tam VH, Panesso D, Tran TT, Miller WR, Arias CA, Reyes J. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824. PMID: 39345182; PMCID: PMC11539226.
      Citations:    Fields:    Translation:HumansCells
    4. Eales BM, Smith J, Pouya N, Hudson CS, Tam VH, Nikolaou M. Rapid Design of Combination Antimicrobial Therapy against Acinetobacter baumannii. Comput Chem Eng. 2025 Jan; 192. PMID: 39781207; PMCID: PMC11709450.
      Citations:    
    5. Truong M, Tolleson S, Ordonez ND, Tam VH. Correlating Advanced Pharmacy Practice Experience Exam Scores and Pharmacist Licensure Status in a Single Program. Am J Pharm Educ. 2024 Sep; 88(9):101255. PMID: 39089630.
      Citations:    Fields:    Translation:Humans
    6. Carvajal LP, Rincon S, Gomez-Villegas SI, Matiz-Gonz?lez JM, Ordo?ez K, Santamaria A, Ospina-Navarro L, Beltran J, Guevara F, Mendez YR, Salcedo S, Porras A, Valencia-Moreno A, Grennia H, Deyanov A, Baptista R, Tam VH, Panesso D, Tran TT, Miller WR, Arias CA, Reyes J. Prevalence of the Cefazolin Inoculum Effect (CzIE) in Nasal Colonizing Methicillin-Susceptible Staphylococcus aureus in Patients from Intensive Care Units in Colombia and Use of a Modified Rapid Nitrocefin Test for Detection. medRxiv. 2024 Jul 11. PMID: 39040169; PMCID: PMC11261917.
      Citations:    
    7. Pouya N, Smith JE, Hudson CS, Teran NS, Tam VH. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255. PMID: 38996872; PMCID: PMC11742240.
      Citations:    Fields:    
    8. Hudson CS, Roy A, Li Q, Joshi AS, Yin T, Kumar A, Sheikh-Hamad D, Tam VH. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145. PMID: 38779756.
      Citations:    Fields:    Translation:AnimalsCells
    9. Eales BM, Smith JE, Pouya N, Teran NS, Miller WR, Tam VH. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193. PMID: 38723696; PMCID: PMC11789364.
      Citations:    Fields:    
    10. Teran NS, Vuong L, Phe K, Lasco TM, Miller WR, Tam VH. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 Jun; 37:100-101. PMID: 38552875; PMCID: PMC11344908.
      Citations: 1     Fields:    Translation:Humans
    11. Teran N, Egge SL, Phe K, Baptista RP, Tam VH, Miller WR. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923. PMID: 38063509; PMCID: PMC10777823.
      Citations: 5     Fields:    Translation:HumansCells
    12. Hudson CS, Smith JE, Eales BM, Kajiji S, Liu X, Truong LD, Tam VH. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441. PMID: 37563789.
      Citations:    Fields:    Translation:HumansAnimals
    13. Hudson CS, Smith JE, Eales BM, Nikolaou M, Tam VH. In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924. PMID: 37433386; PMCID: PMC11344907.
      Citations:    Fields:    Translation:Humans
    14. Nikolaou M, Tam VH. Rapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology. Pharmaceutics. 2023 Jun 07; 15(6). PMID: 37376120; PMCID: PMC10305065.
      Citations: 1     
    15. Gatti M, Tam VH, Gaibani P, Cojutti PG, Viale P, Pea F. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760. PMID: 36804371; PMCID: PMC10498894.
      Citations: 3     Fields:    Translation:Humans
    16. Eales BM, Bai B, Merlau PR, Tam VH. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2). PMID: 36731874; PMCID: PMC9990167.
      Citations:    Fields:    Translation:HumansAnimalsCells
    17. Chua HC, Tam VH. Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools. Open Forum Infect Dis. 2022 Dec; 9(12):ofac626. PMID: 36540388; PMCID: PMC9757694.
      Citations: 2     
    18. Bai B, Eales BM, Huang W, Ledesma KR, Merlau PR, Li G, Yu Z, Tam VH. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927. PMID: 36308002; PMCID: PMC9621070.
      Citations: 5     Fields:    Translation:HumansCells
    19. Kesisoglou I, Eales BM, Merlau PR, Tam VH, Nikolaou M. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212. PMID: 36335752; PMCID: PMC10225978.
      Citations: 2     Fields:    Translation:Humans
    20. Tam VH, Merlau PR, Hudson CS, Kline EG, Eales BM, Smith J, Sofjan AK, Shields RK. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137. PMID: 36031868; PMCID: PMC10205629.
      Citations: 7     Fields:    Translation:HumansCells
    21. Bai B, Chen C, Zhao Y, Xu G, Yu Z, Tam VH, Wen Z. In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. J Glob Antimicrob Resist. 2022 09; 30:66-74. PMID: 35508286.
      Citations: 1     Fields:    Translation:Cells
    22. Zidaru A, Phe K, Lasco TM, Tam VH. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471. PMID: 34849535.
      Citations: 1     Fields:    Translation:Humans
    23. Garcia CR, Malik MH, Biswas S, Tam VH, Rumbaugh KP, Li W, Liu X. Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils. Biomater Sci. 2022 Feb 01; 10(3):633-653. PMID: 34994371.
      Citations: 20     Fields:    
    24. Kesisoglou I, Tam VH, Tomaras AP, Nikolaou M. Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. Comput Chem Eng. 2022 Feb; 158. PMID: 35250117; PMCID: PMC8896896.
      Citations: 5     
    25. Zidaru A, Sofjan AK, Devarajan SR, Tam VH. Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552. PMID: 34922054.
      Citations: 1     Fields:    Translation:HumansCells
    26. Tam VH, Hudson CS, Merlau PR, Shields RK. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346. PMID: 34806561; PMCID: PMC9124231.
      Citations: 1     Fields:    Translation:HumansCells
    27. Eales BM, Hudson CS, Kesisoglou I, Wang W, Nikolaou M, Tam VH. Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics (Basel). 2021 Oct 16; 10(10). PMID: 34680836; PMCID: PMC8532833.
      Citations: 2     
    28. Kesisoglou I, Eales BM, Ledesma KR, Merlau PR, Tam VH, Wang W, Nikolaou M. SIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL. Comput Chem Eng. 2021 Dec; 155. PMID: 34924641; PMCID: PMC8682276.
      Citations: 6     
    29. Tu Y, Wang L, Rong Y, Tam V, Yin T, Gao S, Singh R, Hu M. Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2021 07 01; 10. PMID: 34196607; PMCID: PMC8248983.
      Citations: 5     Fields:    Translation:Animals
    30. Khan S, Phe K, Tam VH. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597. PMID: 33645440.
      Citations: 2     Fields:    Translation:Humans
    31. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. Erratum for Yahav et al., "New ?-Lactam-?-Lactamase Inhibitor Combinations". Clin Microbiol Rev. 2021 Mar 17; 34(2). PMID: 33504504; PMCID: PMC7849239.
      Citations: 26     Fields:    
    32. Tam VH, Abodakpi H, Wang W, Ledesma KR, Merlau PR, Chan K, Altman R, Tran TT, Nikolaou M, Sofjan AK. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183. PMID: 33035321; PMCID: PMC7729384.
      Citations: 14     Fields:    Translation:Cells
    33. Ferry T, Lodise TP, Gallagher JC, Forestier E, Goutelle S, Tam VH, Mohr JF, Roubaud-Baudron C. Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Front Med (Lausanne). 2020; 7:585658. PMID: 33425938; PMCID: PMC7785854.
      Citations: 1     
    34. Ng TM, Heng ST, Oon J, Chan M, Tam VH. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809. PMID: 33258161.
      Citations:    Fields:    Translation:Humans
    35. Tam VH, Lee LS, Ng TM, Lim TP, Cherng BPZ, Adewusi H, Hee KH, Ding Y, Chung SJ, Ling LM, Chlebicki P, Kwa ALH, Lye DC. Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. Microorganisms. 2020 Nov 18; 8(11). PMID: 33217914; PMCID: PMC7698783.
      Citations: 5     
    36. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1). PMID: 33177185; PMCID: PMC7667665.
      Citations: 172     Fields:    Translation:Cells
    37. Zidaru A, Eales BM, Wang W, Merlau PR, Lasco TM, Sofjan AK, Tam VH. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387. PMID: 33166758; PMCID: PMC7770049.
      Citations: 2     Fields:    Translation:HumansCells
    38. Dhaese S, Heffernan A, Liu D, Abdul-Aziz MH, Stove V, Tam VH, Lipman J, Roberts JA, De Waele JJ. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250. PMID: 32710435.
      Citations: 10     Fields:    Translation:Humans
    39. Chan K, Ledesma KR, Wang W, Tam VH. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9). PMID: 32571819; PMCID: PMC7449196.
      Citations: 6     Fields:    Translation:Animals
    40. Phe K, Heil EL, Tam VH. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. J Infect Dis. 2020 07 21; 222(Suppl 2):S132-S141. PMID: 32691832; PMCID: PMC7372216.
      Citations: 15     Fields:    Translation:Humans
    41. Chan K, Wang W, Ledesma KR, Yin T, Tam VH. A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. Bioanalysis. 2020 Apr; 12(7):445-454. PMID: 32343148; PMCID: PMC7270885.
      Citations: 7     Fields:    Translation:Humans
    42. Tam VH, Cohen DN, Ledesma KR, Guillory B, Chan K, Garey KW. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3). PMID: 31871078; PMCID: PMC7038272.
      Citations: 1     Fields:    Translation:Animals
    43. Xie LX, Zhou J, Ledesma KR, Merlau PR, Tam VH. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254. PMID: 31770603.
      Citations:    Fields:    Translation:AnimalsCells
    44. Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TT. Corrigendum to "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways". Case Rep Infect Dis. 2019; 2019:8314349. PMID: 31565449; PMCID: PMC6745093.
      Citations:    
    45. Abodakpi H, Wanger A, Tam VH. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 09; 39(3):473-485. PMID: 31383269; PMCID: PMC6686870.
      Citations: 7     Fields:    Translation:HumansCells
    46. Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5). PMID: 30833428; PMCID: PMC6496039.
      Citations: 87     Fields:    Translation:HumansAnimals
    47. Abodakpi H, Chang KT, Gao S, S?nchez-D?az AM, Cant?n R, Tam VH. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2). PMID: 30530606; PMCID: PMC6355564.
      Citations: 19     Fields:    Translation:HumansCells
    48. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39. PMID: 30710469; PMCID: PMC7437259.
      Citations: 343     Fields:    Translation:Humans
    49. Pogue JM, Tam VH. Toxicity in Patients. Adv Exp Med Biol. 2019; 1145:289-304. PMID: 31364083.
      Citations: 7     Fields:    Translation:Humans
    50. Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TT. In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Rep Infect Dis. 2018; 2018:9095203. PMID: 30675406; PMCID: PMC6323425.
      Citations: 18     
    51. Phe K, Bowers DR, Babic JT, Tam VH. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348. PMID: 30522794.
      Citations: 3     Fields:    Translation:Humans
    52. Tam VH, P?rez C, Ledesma KR, Lewis RE. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294. PMID: 29418013.
      Citations: 7     Fields:    Translation:AnimalsCells
    53. Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538. PMID: 29238962.
      Citations: 37     Fields:    Translation:Humans
    54. Abodakpi H, Chang KT, S?nchez D?az AM, Cant?n R, Lasco TM, Chan K, Sofjan AK, Tam VH. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119. PMID: 29125052.
      Citations: 6     Fields:    Translation:HumansCells
    55. Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155. PMID: 29101084.
      Citations: 1     Fields:    Translation:HumansCells
    56. Babic JT, Manchandani P, Ledesma KR, Tam VH. Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11). PMID: 28848003; PMCID: PMC5655104.
      Citations: 3     Fields:    Translation:Humans
    57. Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8). PMID: 28559261; PMCID: PMC5527625.
      Citations: 10     Fields:    Translation:AnimalsCells
    58. Singh KV, Tran TT, Nannini EC, Tam VH, Arias CA, Murray BE. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7). PMID: 28483961; PMCID: PMC5487651.
      Citations: 12     Fields:    Translation:AnimalsCells
    59. Zhou J, Tran BT, Tam VH. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634. PMID: 28333250.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    60. Tran TT, Tam VH, Murray BE, Arias CA, Singh KV. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6). PMID: 28320712; PMCID: PMC5444151.
      Citations: 1     Fields:    Translation:AnimalsCells
    61. Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, S?nchez-D?az AM, Zamorano L, Oliver A, Cant?n R. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428. PMID: 28158470.
      Citations: 44     Fields:    Translation:HumansCells
    62. Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VH. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5). PMID: 28264853; PMCID: PMC5404596.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    63. Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4). PMID: 28096166; PMCID: PMC5365704.
      Citations: 17     Fields:    Translation:Animals
    64. Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1). PMID: 27799209; PMCID: PMC5192162.
      Citations: 23     Fields:    Translation:Humans
    65. Manchandani P, Dubrovskaya Y, Gao S, Tam VH. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982. PMID: 27697755; PMCID: PMC5075123.
      Citations: 12     Fields:    Translation:HumansAnimals
    66. Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587. PMID: 27543655; PMCID: PMC6296320.
      Citations: 7     Fields:    Translation:Humans
    67. Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DA. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29. PMID: 27239695.
      Citations: 8     Fields:    Translation:Humans
    68. Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77. PMID: 27530844.
      Citations: 3     Fields:    Translation:Humans
    69. Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34. PMID: 26643340; PMCID: PMC4750689.
      Citations: 31     Fields:    Translation:Animals
    70. Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30. PMID: 26612873.
      Citations: 2     Fields:    Translation:Humans
    71. Patel TS, Cottreau JM, Hirsch EB, Tam VH. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8. PMID: 26639227.
      Citations: 1     Fields:    Translation:HumansCells
    72. Zhang D, Wu L, Chow DS, Tam VH, Rios DR. Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates. J Pharm Biomed Anal. 2016 Jan 05; 117:227-31. PMID: 26372947.
      Citations: 7     Fields:    Translation:Humans
    73. Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov; 59(11):7121-3. PMID: 26324262; PMCID: PMC4604353.
      Citations: 11     Fields:    Translation:HumansCells
    74. Bhagunde PR, Nikolaou M, Tam VH. Modeling Heterogeneous Bacterial Populations Exposed to Antibiotics: The Logistic-Dynamics Case. AIChE J. 2015 Aug; 61(8):2385-2393. PMID: 37206682; PMCID: PMC10195107.
      Citations: 4     
    75. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5. PMID: 25712362; PMCID: PMC4394818.
      Citations: 35     Fields:    Translation:AnimalsCells
    76. Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3. PMID: 25712358; PMCID: PMC4394766.
      Citations: 5     Fields:    Translation:Animals
    77. Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7. PMID: 25652747.
      Citations: 24     Fields:    Translation:Humans
    78. Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4. PMID: 25665726.
      Citations: 28     Fields:    Translation:Humans
    79. Phe K, Dao D, Palmer HR, Tam VH. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370. PMID: 25403674; PMCID: PMC4335838.
      Citations: 5     Fields:    Translation:Cells
    80. Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81. PMID: 25381169.
      Citations: 4     Fields:    Translation:Humans
    81. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34. PMID: 25459221.
      Citations: 149     Fields:    Translation:Humans
    82. Abdelraouf K, Tam VH. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339. PMID: 25225341; PMCID: PMC4187904.
      Citations: 1     Fields:    Translation:AnimalsCells
    83. Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8. PMID: 25136012; PMCID: PMC4249357.
      Citations: 10     Fields:    Translation:HumansCells
    84. Zhang D, Rios DR, Tam VH, Chow DS. Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. J Pharm Biomed Anal. 2014 Oct; 99:67-73. PMID: 25072843.
      Citations: 4     Fields:    Translation:Humans
    85. Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VH. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44. PMID: 24957824; PMCID: PMC4135838.
      Citations:    Fields:    Translation:HumansCells
    86. Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21. PMID: 24797063.
      Citations: 11     Fields:    Translation:Humans
    87. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2. PMID: 24733472; PMCID: PMC4068554.
      Citations: 25     Fields:    Translation:AnimalsCells
    88. Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7. PMID: 24674388.
      Citations: 5     Fields:    Translation:HumansCells
    89. Ng TM, Lye DC, Chan M, Tam VH. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9. PMID: 24359843.
      Citations: 1     Fields:    Translation:Humans
    90. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64. PMID: 24016799; PMCID: PMC3849129.
      Citations: 16     Fields:    Translation:AnimalsCells
    91. Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7. PMID: 23977938.
      Citations:    Fields:    Translation:HumansCells
    92. He J, Gao S, Hu M, Chow DS, Tam VH. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10. PMID: 23341128; PMCID: PMC3625435.
      Citations: 20     Fields:    Translation:Animals
    93. Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar; 57(3):1270-4. PMID: 23263001; PMCID: PMC3591924.
      Citations: 17     Fields:    Translation:HumansCells
    94. Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis. 2013 Mar 01; 207(5):786-93. PMID: 23242537.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    95. Tam VH, Chang KT, Yang Z, Newman J, Hu M. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Feb; 57(2):1062-4. PMID: 23229481; PMCID: PMC3553694.
      Citations: 5     Fields:    Translation:Cells
    96. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 2012 Nov; 56(11):5724-7. PMID: 22908162; PMCID: PMC3486600.
      Citations: 31     Fields:    Translation:Animals
    97. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9. PMID: 22687519; PMCID: PMC3421883.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    98. Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84. PMID: 22610031.
      Citations: 3     Fields:    Translation:Humans
    99. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7. PMID: 22526311; PMCID: PMC3393460.
      Citations: 63     Fields:    Translation:Cells
    100. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40. PMID: 22330927; PMCID: PMC3346582.
      Citations: 24     Fields:    Translation:HumansCells
    Tam's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (248)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Same Department Expand Description
    Explore
    _